Compared to GLP-1 analogues, sitagliptin treatment did not seem to increase the risk of hypoglycemia, although a previous meta-analysis showed that GLP-1 analogues did not similarly increase the risk of hypoglycemia [24]. The gene discussed is GCG; the disease is Hypoglycemia.